AstraZeneca show higher revenues than väntant for the first quarter of 2016. the figure landed at $ 6.115 billion. Analysts’ average forecast was here sales of $ 5.952 billion.
The pharmaceutical company reported earnings per share Core (Core) at 0.95 dollars in the first quarter of 2016, it is clear from the interim report.
There was something worse than analysts’ expectations of an average of 0:96 per share, according to SME Direkt survey.
reported operating profit was $ 1.038 billion, which was better-than-expected 869 million. Operating margin landed at 17 percent, more than expected 14.6 percent.
The company reported non-recurring items of -555 million, better than expected -741 million.
Brilinta, which belongs , one of Astra’s growth platforms, reported sales of $ 181 million, compared to the expected 184 million.
No comments:
Post a Comment